Navigation Links
The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
Date:7/25/2013

NEW YORK, July 25, 2013 /PRNewswire/ -- The Galien Foundation today announced the 2013 nominees for the seventh annual Prix Galien Awards. The Prix Galien Award is considered the biomedical industry's highest accolade and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices.

(Logo: http://photos.prnewswire.com/prnh/20130709/NY43872LOGO )

This year brings the highest number of nominees since the inception of the Prix Galien USA – a reflection of the United States continuing to lead the world in first approval of new medicines.  Ranging from a tablet drug for the treatment of metastatic colorectal cancer, to a ground-breaking treatment for cystic fibrosis, and the first and only drug available to reduce toxic plasma methotrexate levels, nominees include biomedical products that advance the human condition and which were approved by the U.S. Food and Drug Administration (FDA) during the past five years.

Nominees for the Prix Galien USA 2013 Awards are: Best Biotechnology Product (Nominees)BOTOX® (onabotulinumtoxinA) for Chronic MigraineAllergan, Inc.Voraxaze® (glucarpidase)BTG International Inc.MenHibrix® [Meningococcal Groups C and Y and
Haemophilus b Tetanus Toxoid Conjugate Vaccine]

GlaxoSmithKline VaccinesErwinaze® (asparaginase Erwinia chrysanthemi)

Jazz PharmaceuticalsFluMist® Quadrivalent

(Influenza Vaccine Live, Intranasal)MedImmune/AstraZenecaZostavax® (Zoster Vaccine Live)Merck 

HEMACORD™ (HPC, Cord Blood)New York Blood Center's
Howard P. Milstein Cord Blood CenterGattex® (teduglutide)NPS PharmaceuticalsKyprolis® (carfilzomib) for Injection

Onyx Pharmaceuticals, Inc.Gintuit™ (Allogeneic Cultured Keratinocytes and
Fibroblasts in Bovine Collagen)

OrganogenesisKineret® (anakinra)

SobiTbo-filgrastim (XM02)

Teva PharmaceuticalsJETREA® (ocriplasmin)

ThromboGenicsBest Pharmaceutical Agent (Nominees)AMPYRA® (dalfampridine)
Extended Release Tablets, 10 mg

Acorda TherapeuticsBELVIQ® (lorcaserin HCl)

Arena PharmaceuticalsCAPRELSA® (vandetanib)

AstraZenecaStivarga® (regorafenib)

Bayer HealthCareEliquis® (apixaban)Bristol-Myers Squibb & PfizerBanzel® (rufinamide)EisaiZelboraf® (vemurafenib)GenentechSirturo® (bedaquiline)JanssenXarelto® (rivaroxaban)JanssenZytiga® (abiraterone acetate)JanssenXtandi® (enzalutamide)

MedivationXALKORI® (crizotinib)

PfizerXeljanz® (tofacitinib)

PfizerOxyContin®
(reformulated oxycodone HCl controlled release)

Purdue PharmaNeupro® (Rotigotine Transdermal System)

UCBVimpat® (lacosamide) CV

UCBKALYDECO™ (ivacaftor)

Vertex PharmaceuticalsBest Medical Technology (Nominees)COMBIVENT® RESPIMAT®
(ipratropium bromide and albuterol) Inhalation SprayBoehringer IngelheimAlair® Bronchial Thermoplasty SystemBoston ScientificS-ICD® System
(subcutaneous implantable defibrillator)Boston ScientificNovoTTF™ Therapy

Novocurecoflex® Interlaminar Stabilization™ deviceParadigm Spine, LLCElecsys® Testosterone IIRoche Auvi-Q™ (epinephrine injection, USP)Sanofi  Trevo® ProVue™ RetrieverStrykerCentraSight®VisionCare 

The Prix Galien USA Committee, comprised of nine renowned leaders in biomedical industry and academia, including five Nobel Laureates, is responsible for evaluating nominees. Winners will be honored at the Prix Galien Award Ceremony on October 22, 2013 at 6:00 p.m., at the American Museum of Natural History in New York City.  Registration is open to the Prix Galien USA Award Ceremony and can be accessed here.

"Biomedical research cannot exist without those who are willing to push innovation and extract understanding and attention in the details," remarked Bruno Cohen, Chairman of the Galien Foundation.  "This year's nominees are catalysts for the development of disease-altering advances through biopharmaceutical and medical innovation.  We are proud to honor those in the field who exemplify these values; the same values that the Galien Foundation continually upholds, distinguishing these awards as the best in the world."

About the Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information visit www.galienfoundation.org.

Galien Foundation Media Contact:
Jon Florio
Makovsky
jflorio@makovsky.com
212-508-9667


'/>"/>
SOURCE Galien Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
2. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
3. The Galien Foundation Announces New "Best Medical Technology" Award Category for 2012 Prix Galien USA Awards Program
4. Organovo and Methuselah Foundation Announce Funding of Bioprinting Research at Research Institutions
5. National Association of Specialty Pharmacy (NASP) Partners with the Patient Access Network (PAN) Foundation to Host Charity Golf Outing at Upcoming Meeting
6. WED/RLS Foundation Sheds Light On TranquilMeds Drug-free Solution
7. Austen BioInnovation Institute Gains Funding from The Burton D. Morgan Foundation to Accelerate Biomedical Innovation, Train Young Professionals
8. Promising Parkinsons Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
9. Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
10. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
11. Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):